Vivani Medical Files 8-K, Relocates Offices
Ticker: VANI · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1266806
Sentiment: neutral
Topics: corporate-action, filing-update
TL;DR
Vivani Medical moved its HQ to Alameda, CA. Formerly Second Sight Medical.
AI Summary
Vivani Medical, Inc. filed an 8-K on September 26, 2024, to report other events and financial statements. The filing indicates a change in the company's principal executive offices to 1350 S. Loop Road, Alameda, California 94502. The company was formerly known as Second Sight Medical Products Inc.
Why It Matters
This filing signals a change in the company's operational base, which could impact logistics, employee location, and potentially future business strategies.
Risk Assessment
Risk Level: low — This is a routine filing reporting administrative changes and financial statements, with no immediate financial or operational risks indicated.
Key Players & Entities
- Vivani Medical, Inc. (company) — Registrant
- September 26, 2024 (date) — Date of Report
- 1350 S. Loop Road Alameda, California 94502 (location) — New principal executive offices
- Second Sight Medical Products Inc (company) — Former company name
FAQ
What is the new address for Vivani Medical, Inc.'s principal executive offices?
The new address for Vivani Medical, Inc.'s principal executive offices is 1350 S. Loop Road, Alameda, California 94502.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 26, 2024.
What was Vivani Medical, Inc. formerly known as?
Vivani Medical, Inc. was formerly known as Second Sight Medical Products Inc.
What is the state of incorporation for Vivani Medical, Inc.?
Vivani Medical, Inc. is incorporated in Delaware.
What is the telephone number listed for the agent for service at Vivani Medical, Inc.?
The telephone number listed for the agent for service at Vivani Medical, Inc. is (415) 506-8462.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-09-26 08:46:00
Filing Documents
- vani-20240926.htm (8-K) — 36KB
- ex991_1.htm (EX-99.1) — 28KB
- 0001753926-24-001628.txt ( ) — 260KB
- vani-20240926_def.xml (EX-101.DEF) — 1KB
- vani-20240926_pre.xml (EX-101.PRE) — 29KB
- vani-20240926_cal.xml (EX-101.CAL) — 1KB
- vani-20240926_lab.xml (EX-101.LAB) — 42KB
- vani-20240926.xsd (EX-101.SCH) — 4KB
- vani-20240926_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 26, 2024, Vivani Medical, Inc. (the "Company") announced it received regulatory approval to initiate a first in human clinical trial, known as the LIBERATE-1, with the Company's GLP-1 (exenatide) implant in obese and overweight individuals in Australia. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Vivani Medical, Inc. on September 26 , 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) .
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIVANI MEDICAL, INC. Date: September 26 , 2024 By: /s/ Donald Dwyer Name: Donald Dwyer Title: Chief Business Officer